Company intelligence / Profile preview
Archigen Biotech Limited
Cambridge, Cambridgeshire, United Kingdom
- Ownership
- Private
- Employees
- ~9
- Development stage
- Dissolved
01
Overview
Archigen Biotech completed Phase 3 clinical trials for SAIT101 (rituximab biosimilar) in 2020. While the clinical trial results were valid, Samsung Biologics and AstraZeneca judged that their Rituxan biosimilar would not have the desired competitiveness as other Rituxan biosimilars had already hit the market, so they decided to stop its development.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AstraZenecaSamsung BioLogics
Beyond the preview
Go deeper on Archigen Biotech Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Archigen Biotech Limited.